Literature DB >> 11403229

OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.

R M van Praag1, J M Prins, M T Roos, P T Schellekens, I J Ten Berge, S L Yong, H Schuitemaker, A J Eerenberg, S Jurriaans, F de Wolf, C H Fox, J Goudsmit, F Miedema, J M Lange.   

Abstract

Activation of resting T cells has been proposed to purge the reservoir of HIV-1-infected resting CD4+ T cells. We therefore treated three HIV-1-infected patients on antiretroviral therapy with OKT3, a CD3 monoclonal antibody, and recombinant human IL-2. Here we report the profound and partially long-lasting host responses induced by the OKT3 and IL-2 treatment. OKT3/IL-2 induced a strong but transient release of plasma cytokines and chemokines. The percentage CD4+ and CD8+ cells in the blood expressing the activation marker CD38 transiently increased to almost 100%, and in lymph nodes we "observed" a 10-fold increase in the number of dividing Ki67+ cells and increased numbers of apoptotic cells. Following OKT3/IL-2 treatment, a long-lasting depletion of CD4+ cells in the peripheral blood and lymph nodes occurred, suggesting the physical deletion of these cells. Increases in CD4+T cell numbers during the two year followup period were due mainly to increased memory cell numbers. CD8+ cells were also depleted in the blood, but less severely in lymph nodes, and returned to baseline levels within several weeks.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403229     DOI: 10.1023/a:1011091300321

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  37 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

Authors:  R P Bucy; R D Hockett; C A Derdeyn; M S Saag; K Squires; M Sillers; R T Mitsuyasu; J M Kilby
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

3.  In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.

Authors:  L Chatenoud; C Ferran; C Legendre; I Thouard; S Merite; A Reuter; Y Gevaert; H Kreis; P Franchimont; J F Bach
Journal:  Transplantation       Date:  1990-04       Impact factor: 4.939

4.  Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies.

Authors:  T F Müller; S O Grebe; M C Neumann; J Heymanns; K Radsak; H Sprenger; H Lange
Journal:  Transplantation       Date:  1997-11-27       Impact factor: 4.939

5.  Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.

Authors:  C Fraser; N M Ferguson; A C Ghani; J M Prins; J M Lange; J Goudsmit; R M Anderson; F de Wolf
Journal:  AIDS       Date:  2000-04-14       Impact factor: 4.177

6.  Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.

Authors:  R T Davey; D G Chaitt; S C Piscitelli; M Wells; J A Kovacs; R E Walker; J Falloon; M A Polis; J A Metcalf; H Masur; G Fyfe; H C Lane
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

7.  Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.

Authors:  J A Kovacs; M Baseler; R J Dewar; S Vogel; R T Davey; J Falloon; M A Polis; R E Walker; R Stevens; N P Salzman; Lane H. Clifford
Journal:  N Engl J Med       Date:  1995-03-02       Impact factor: 91.245

8.  Toxicity of OKT3 increases with dosage: a controlled study in renal transplant recipients.

Authors:  K J Parlevliet; F J Bemelman; S L Yong; C E Hack; J Surachno; J M Wilmink; I J ten Berge; P T Schellekens
Journal:  Transpl Int       Date:  1995       Impact factor: 3.782

9.  Biphasic granulocytopenia after administration of the first dose of OKT3.

Authors:  F J Bemelman; S Buysmann; S L Yong; F N van Diepen; P T Schellekens; R J ten Berge
Journal:  J Lab Clin Med       Date:  1995-12

10.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

View more
  75 in total

1.  Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Authors:  Frank Wolschendorf; Alberto Bosque; Takao Shishido; Alexandra Duverger; Jennifer Jones; Vicente Planelles; Olaf Kutsch
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  Combinatorial latency reactivation for HIV-1 subtypes and variants.

Authors:  John C Burnett; Kwang-Il Lim; Arash Calafi; John J Rossi; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

Review 3.  New therapeutic strategies targeting transmembrane signal transduction in the immune system.

Authors:  Alexander B Sigalov
Journal:  Cell Adh Migr       Date:  2010-04-24       Impact factor: 3.405

4.  CRISPR-mediated Activation of Latent HIV-1 Expression.

Authors:  Prajit Limsirichai; Thomas Gaj; David V Schaffer
Journal:  Mol Ther       Date:  2015-11-26       Impact factor: 11.454

Review 5.  Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

Authors:  Catalina Méndez; Chantelle L Ahlenstiel; Anthony D Kelleher
Journal:  World J Virol       Date:  2015-08-12

Review 6.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

7.  Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation.

Authors:  Hung-Chih Yang; Lin Shen; Robert F Siliciano; Joel L Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-31       Impact factor: 11.205

8.  Rational design of drugs that induce human immunodeficiency virus replication.

Authors:  Dean H Hamer; Sven Bocklandt; Louise McHugh; Tae-Wook Chun; Peter M Blumberg; Dina M Sigano; Victor E Marquez
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  Cellular reservoirs of HIV-1 and their role in viral persistence.

Authors:  Aikaterini Alexaki; Yujie Liu; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2008-09       Impact factor: 1.581

Review 10.  From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Authors:  Liang Shan; Robert F Siliciano
Journal:  Bioessays       Date:  2013-04-24       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.